-
Anne Wojcicki Buys Back 23andMe for $305M, Promises Data Security
Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8.
Jul 2, 2025
-
Real-Time Drug Monitoring: A New Era for Drug Discovery and Development
Bio-IT World | In Stanford University's engineering labs, Tom Soh has been wrestling with a paradox that has plagued medicine for decades. While modern jet engines generate terabytes of data every hour to prevent catastrophic failures, the human body gets monitored only during annual checkups or after something has already gone wrong.
Jul 1, 2025
-
UK Study Demonstrates Real-World Value of Genetic Testing for Drug Prescribing
Bio-IT World | The UK's National Health Service is pioneering a new approach to precision medicine through pharmacogenomic testing that could transform how doctors prescribe medications and significantly reduce healthcare costs. Early results from the NHS PROGRESS trial suggest that genetic testing can guide prescribing decisions for nearly all patients, with one in four participants having their prescriptions adjusted for safer or more effective treatment.
Jun 26, 2025


